Passamonti F - Search Results

1

Blast phase of essential thrombocythemia: A single center study.

Passamonti F, Rumi E, Arcaini L, Elena C, Castagnola C, Zappasodi P, Bernasconi P, Pietra D, Pascutto C, Cazzola M, Lazzarino M. Passamonti F, et al. Am J Hematol. 2009 Oct;84(10):641-4. doi: 10.1002/ajh.21496. Am J Hematol. 2009. PMID: 19691103 Free article.

2

Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.

Brusamolino E, Passamonti F, Pagnucco G, Castagnola C, Lazzarino M, Bernasconi C. Brusamolino E, et al. Among authors: passamonti f. Haematologica. 1998 Apr;83(4):323-8. Haematologica. 1998. PMID: 9592982

3

Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.

Passamonti F, Brusamolino E, Lazzarino M, Baraté C, Klersy C, Orlandi E, Canevari A, Castelli G, Merante S, Bernasconi C. Passamonti F, et al. Haematologica. 2000 Oct;85(10):1011-8. Haematologica. 2000. PMID: 11025590

4

Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.

Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Baraté C, Pagnucco G, Baio A, Franchini P, Lazzarino M, Bernasconi C. Brusamolino E, et al. Among authors: passamonti f. Haematologica. 2000 Oct;85(10):1032-9. Haematologica. 2000. PMID: 11025593 Clinical Trial.

5

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.

Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, Passamonti F, Klersy C, Pascutto C, Canevari-Sciorati A, Lazzarino M. Corso A, et al. Among authors: passamonti f. Haematologica. 2001 Apr;86(4):394-8. Haematologica. 2001. PMID: 11325645

6

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, Baratè C, Canevari A, Corso A, Bernasconi P, Cazzola M, Lazzarino M. Passamonti F, et al. Br J Haematol. 2002 Mar;116(4):855-61. doi: 10.1046/j.0007-1048.2002.03367.x. Br J Haematol. 2002. PMID: 11886392 Free article.

7

Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.

Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, Volpe G, Pistorio A, Giardini I, Rocca B, Caresana M, Lazzarino M, Bernasconi C. Bernasconi P, et al. Among authors: passamonti f. Leukemia. 2002 Oct;16(10):2078-83. doi: 10.1038/sj.leu.2402638. Leukemia. 2002. PMID: 12357360

8

Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M. Passamonti F, et al. Haematologica. 2003 Jan;88(1):13-8. Haematologica. 2003. PMID: 12551821

9

Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.

Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, Pascutto C, Morra E, Lazzarino M, Cazzola M. Passamonti F, et al. Haematologica. 2003 Oct;88(10):1123-9. Haematologica. 2003. PMID: 14555308

10

Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.

Passamonti F, Lazzarino M. Passamonti F, et al. Leuk Lymphoma. 2003 Sep;44(9):1483-8. doi: 10.3109/10428190309178768. Leuk Lymphoma. 2003. PMID: 14565648 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

432 results

Search Page

Filters